Caxton Corp Vectiv Bio Holding Ag Transaction History

Caxton Corp

$23.3 Million
Q3 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 15, 2023	BUY	$7.34 - $9.15 $3,148 - $3,925	429 Added 0.27%	156,651 $1.33 Million
Q4 2022 Feb 14, 2023	BUY	$7.79 - $8.98 $119,646 - $137,923	15,359 Added 10.9%	156,222 $1.35 Million
Q3 2022 Nov 14, 2022	SELL	$4.7 - $6.07 $252,455 - $326,043	-53,714 Reduced 27.61%	140,863 $845,000
Q2 2022 Aug 15, 2022	BUY	$4.2 - $6.55 $817,223 - $1.27 Million	194,577 New	194,577 $1.05 Million

Others Institutions Holding VECT

# of Institutions

1

Shares Held

510K

Call Options Held

0

Put Options Held

0

Regency Capital Management Inc.\De

510K
Shares

$0
0.0% of portfolio

About VectivBio Holding AG

Ticker VECT
Exchange NASDAQ
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...

More about VECT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Corp with notifications on news.